first
case
finland
femal
chines
tourist
left
wuhan
januari
arriv
finland
januari
first
symptom
runni
nose
januari
nausea
januari
high
fever
weak
cough
sought
medic
attent
januari
suspicion
led
direct
transfer
lapland
central
hospit
rovaniemi
isol
sampl
januari
laboratori
confirm
infect
figur
infect
confirm
nasopharyng
sampl
januari
helsinki
univers
hospit
laboratori
huslab
confirm
finnish
institut
health
welfar
thl
tabl
laboratori
perform
realtim
rtpcr
test
three
target
envelop
e
rnadepend
rna
polymeras
rdrp
nucleocapsid
n
primer
probe
base
corman
et
al
method
cycl
threshold
ct
valu
consid
neg
case
mild
symptom
throughout
isol
period
test
pcrneg
februari
sampl
consid
asymptomat
discharg
hospit
februari
one
addit
sampl
serolog
pcr
taken
februari
respect
altogeth
close
contact
identifi
could
reach
fourteen
still
finland
place
quarantin
day
inform
three
close
contact
left
countri
commun
compet
author
respect
countri
remain
four
close
contact
contact
detail
two
close
contact
close
coexpos
therefor
sampl
day
first
symptom
index
case
followup
contact
end
februari
without
secondari
transmiss
event
viru
isol
biosafeti
level
laboratori
vero
cell
day
nasopharyng
swab
np
nasopharyng
aspir
npa
specimen
tabl
sampl
inocul
cell
h
fresh
cultur
medium
eagl
minimum
essenti
medium
emem
supplement
fetal
bovin
serum
fb
penicillin
streptomycin
mm
lglutamin
mm
hepe
ad
incub
day
incub
half
cultur
blindpassag
onto
fresh
vero
cell
rest
origin
passag
incub
day
incub
clear
cpe
detect
npaorigin
passag
propag
stock
viru
done
passag
low
viru
dose
vero
cell
viru
cultur
harvest
day
viru
concentr
follow
rtpcr
ct
valu
viru
passag
day
incub
passag
day
cpe
wherea
np
specimen
remain
ct
valu
serum
sampl
collect
index
case
day
onset
first
symptom
figur
presenc
serum
igm
igg
antibodi
analys
immunofluoresc
assay
ifa
base
vero
cell
infect
passag
patient
isol
viru
transfer
onto
microscop
slide
fix
aceton
figur
serum
sampl
index
case
serial
dilut
incub
h
igm
min
igg
antibodi
visualis
fluorescein
isothiocyan
fitc
conjug
antihuman
igm
igg
antibodi
antibodi
undetect
day
onset
symptom
igg
titr
rose
igm
titr
day
respect
tabl
random
serum
sampl
staff
member
univers
helsinki
n
show
specif
bind
dilut
greater
figur
mock
vero
cell
collect
day
post
infect
lyse
laemmli
sampl
buffer
western
blot
wb
lysat
perform
describ
previous
dilut
convalesc
serum
day
identifi
n
e
protein
band
figur
higher
exposur
band
detect
even
serum
dilut
figur
neutralis
antibodi
level
measur
duplic
mn
test
laboratori
serum
sampl
heatinactiv
min
serial
dilut
start
emem
supplement
heatinactiv
fb
antibiot
fifti
unit
pfu
strain
ad
serum
dilut
incub
h
vero
cell
ad
mix
mixtur
incub
plate
day
neutralis
assess
cpe
neutralis
endpoint
determin
endpoint
serum
inhibit
infect
observ
cpe
inocul
cell
diagnost
serum
sampl
index
case
three
asymptomat
close
contact
studi
mn
test
acut
phase
infect
neutralis
antibodi
detect
patient
seroconvert
neutralis
antibodi
day
titr
increas
day
tabl
serum
specimen
confirm
toxic
infect
cell
serum
sampl
taken
three
close
contact
test
neg
mn
test
also
test
serum
sampl
collect
finnish
subject
age
year
test
neg
sera
known
posit
igg
human
coronaviru
rabbit
guinea
pig
antibodi
sarscov
n
protein
could
neutralis
viru
investig
carri
accord
gener
data
protect
regul
regul
eu
direct
finnish
person
data
act
finlex
finnish
communic
diseas
act
finlex
allow
sampl
diagnost
surveil
purpos
convalesc
serum
sampl
obtain
februari
inform
consent
patient
research
permit
helsinki
univers
hospit
laboratori
finnish
popul
serum
sampl
collect
studi
protocol
approv
ethic
committe
depart
medicin
helsinki
univers
hospit
permiss
serum
sampl
univers
helsinki
staff
member
use
inform
consent
earli
phase
outbreak
confirm
case
outsid
china
mostli
import
among
travel
wuhan
first
case
finland
detect
januari
among
first
import
case
europ
case
present
mild
symptom
without
pneumonia
runni
nose
nausea
high
fever
cough
muscular
weak
fatigu
secondari
transmiss
event
detect
despit
activ
followup
lapland
hospit
district
thl
march
addit
laboratoryconfirm
case
detect
finland
mani
travelrel
mostli
northern
itali
austria
also
local
transmiss
travelrel
case
risk
widespread
nation
commun
transmiss
infect
european
union
european
econom
area
unit
kingdom
come
week
consid
high
european
centr
diseas
prevent
control
sequenc
viral
genom
patient
nearli
ident
refer
strain
wuhan
reflect
earli
import
china
later
sequenc
inform
finland
march
show
cluster
strain
circul
itali
see
nextstrainorgncov
current
guidelin
world
health
organ
test
recommend
collect
acut
convalesc
serum
sampl
patient
serolog
test
support
identif
immun
respons
specif
viral
pathogen
nucleic
acid
found
also
anal
swab
blood
howev
detect
serum
sampl
case
yet
limit
data
avail
antibodi
respons
infect
studi
need
better
understand
seropreval
antibodi
differ
corona
virus
popul
role
antibodi
risk
diseas
accord
earlier
find
found
igm
igg
titr
low
undetect
day
second
day
admiss
hospit
yet
increas
day
ie
day
first
sampl
use
detect
method
beyond
ifa
well
recombin
antigen
analys
sampl
larger
number
patient
shed
light
time
first
appear
antisarscov
antibodi
rang
day
day
igm
igg
antibodi
respect
wb
serum
sampl
collect
convalesc
show
promin
respons
n
protein
confirm
role
main
candid
diagnost
target
antibodi
test
howev
patient
serum
appear
recognis
also
e
protein
process
protein
although
wb
detect
mainli
linear
epitop
strong
antibodi
respons
protein
correl
well
result
mn
assay
monitor
bind
antibodi
suggest
sensit
method
measur
function
neutralis
antibodi
serolog
detect
human
coronaviru
hcov
infect
howev
hcov
sampl
also
crossreact
sarscov
elisa
test
cpebas
mn
test
use
live
viru
appear
specif
labori
conduct
requir
laboratori
increas
least
neutralis
antibodi
indic
posit
respons
detect
day
first
symptom
day
antibodi
level
still
increas
find
indic
mn
assay
specif
function
antibodi
could
appli
surveil
popul
immun
viru
assay
use
confirmatori
tool
specif
develop
access
diagnost
tool
assay
base
detect
bind
antibodi
previou
studi
patient
sarscov
infect
indic
median
time
seroconvers
day
time
patient
igg
viru
igm
igg
antibodi
present
within
week
onset
symptom
studi
suggest
earli
convalesc
patient
may
suitabl
sourc
therapeut
antibodi
accord
find
recent
preprint
report
patient
admit
hospit
confirm
infect
china
indic
median
time
seroconvers
day
depend
immunolog
assay
use
neutralis
antibodi
detect
close
contact
control
popul
sampl
collect
finland
low
preval
antibodi
middl
east
respiratori
syndrom
coronaviru
report
gener
popul
qatar
metaanalysi
seropreval
sarscov
among
differ
human
popul
yield
overal
low
seropreval
although
slightli
higher
among
healthcar
worker
other
close
contact
sar
patient
bind
neutralis
hcov
antibodi
found
higher
older
adult
total
serum
sampl
healthi
adult
antibodi
respect
children
age
group
year
found
seroposit
respect
suggest
late
seroconvers
sar
patient
reduc
valu
serolog
assay
incub
initi
phase
sar
serolog
test
suggest
confirm
sar
infect
understand
better
kinet
specif
sensit
assay
develop
serolog
test
may
help
contact
trace
cluster
role
diagnos
acut
past
infect
